Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 2× · see citing works

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742 · see citing works

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works

Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA

Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728 · see citing works

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · see citing works

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104974 · Cited by 899 · see citing works

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Wang, P., Casner, R. G., Nair, M. S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P. D., Huang, Y., Shapiro, L., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.007 · Cited by 636 · see citing works

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., Triccas, J. A., Khoury, D. S., & Davenport, M. P. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00267-6 · Cited by 590 · see citing works

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Wall, E. C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P., Hatipoglu, E., Ngai, Y., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01290-3 · Cited by 491 · see citing works

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Kremsner, P., Mann, P., Bosch, J., Fendel, R., Gabor, J. J., Kreidenweiss, A., Kroidl, A., Leroux-Roels, I., Leroux-Roels, G., Schindler, C., et al. (2020) · doi:10.1101/2020.11.09.20228551 · Cited by 199 · see citing works

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Gilbert, P. B., Montefiori, D. C., McDermott, A. B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., et al. (2022) · Science · doi:10.1126/science.abm3425 · Cited by 1,137 · see citing works

Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of <i>in vivo</i> imaging

Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., & Im, H.-J. (2022) · Theranostics · doi:10.7150/thno.77259 · Cited by 282 · see citing works

Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection

Khoury, D. S., Schlub, T. E., Cromer, D., Steain, M. C., Fong, Y., Gilbert, P. B., Subbarao, K., Triccas, J. A., Kent, S. J., & Davenport, M. P. (2023) · Emerging infectious diseases · doi:10.3201/eid2902.221422 · Cited by 148 · see citing works

Predicting the efficacy of variant-modified COVID-19 vaccine boosters

Khoury, D. S., Docken, S. S., Subbarao, K., Kent, S. J., Davenport, M. P., & Cromer, D. (2023) · Nature Medicine · doi:10.1038/s41591-023-02228-4 · Cited by 102 · see citing works

The advances of adjuvants in mRNA vaccines

Xie, C., Yao, R., & Xia, X. (2023) · npj Vaccines · doi:10.1038/s41541-023-00760-5 · Cited by 98 · see citing works

Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation

Huang, Y., Borisov, O., Kee, J. J., Carpp, L. N., Wrin, T., Cai, S., Sarzotti‐Kelsoe, M., McDanal, C. B., Eaton, A., Pajón, R., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-03154-6 · Cited by 72 · see citing works

Monoclonal antibody levels and protection from COVID-19

Stadler, E., Burgess, M. T., Schlub, T. E., Khan, S. R., Chai, K. L., McQuilten, Z., Wood, E. M., Polizzotto, M. N., Kent, S. J., Cromer, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40204-1 · Cited by 61 · see citing works

Viral vector and nucleic acid vaccines against COVID-19: A narrative review

Khoshnood, S., Ghanavati, R., Shirani, M., Ghahramanpour, H., Sholeh, M., Shariati, A., Sadeghifard, N., & Heidary, M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.984536 · Cited by 34 · see citing works

An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)

Bahrami, A. A., Azargoonjahromi, A., Sadraei, S., Aarabi, A., Payandeh, Z., & Rajabibazl, M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00339-3 · Cited by 32 · see citing works

COVID‐19: Clinical status of vaccine development till date

Kumar, S., Basu, M., Ghosh, P., Ansari, A., & Ghosh, M. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15552 · Cited by 18 · see citing works

Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models

Corleis, B., Hoffmann, D., Rauch, S., Fricke, C., Roth, N., Gergen, J., Kovacikova, K., Schlottau, K., Halwe, N. J., Ulrich, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36110-1 · Cited by 22 · see citing works

Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III)

Ryzhikov, A. B., Ryzhikov, E. A., Bogryantseva, M. P., Вячеславовна, У. С., Августовна, Н. Е., Даниленко, Е. Д., Pyankov, S. A., Gudymo, A. S., Алексеевна, М. А., Сергеевна, О. Г., et al. (2023) · Vaccines · doi:10.3390/vaccines11050998 · Cited by 20 · see citing works

COVID-19 Vaccines: Where Did We Stand at the End of 2023?

Lundstrom, K. H. (2024) · Viruses · doi:10.3390/v16020203 · Cited by 19 · see citing works

Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines

Hromić‐Jahjefendić, A., Lundstrom, K. H., Adilović, M., Aljabali, A. A. A., Tambuwala, M. M., Serrano‐Aroca, Á., & Uversky, V. N. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103508 · Cited by 13 · see citing works

Analysis of BNT162b2‐ and CVnCoV‐elicited sera and of convalescent sera toward SARS‐CoV‐2 viruses

Hein, S., Herrlein, M., Mhedhbi, I., Bender, D., Haberger, V., Benz, N. I., Eisert, J., Stingl, J., Dreher, M., Oberle, D., et al. (2021) · Allergy · doi:10.1111/all.15189 · Cited by 11 · see citing works

Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy

Stoddard, M., Yuan, L., Sarkar, S., Mangalaganesh, S., Nolan, R. P., Bottino, D. C., Hather, G., Hochberg, N. S., White, L. F., & Chakravarty, A. (2023) · Vaccines · doi:10.3390/vaccines11040806 · Cited by 7 · see citing works

Fcγ receptor-dependent antibody effector functions are required for vaccine protection against infection by antigenic variants of SARS-CoV-2Preprint

Mackin, S., Desai, P., Whitener, B. M., Karl, C. E., Liu, M., Baric, R. S., Edwards, D. K., Chicz, T. M., McNamara, R. P., Alter, G., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.27.518117 · Cited by 6 · see citing works

Recent progress on drugs discovery study for treatment of COVID-19: repurposing existing drugs and current natural bioactive molecules

Oktavianawati, I., Santoso, M., Bakar, M. F. A., Kim, Y., & Fatmawati, S. (2023) · Applied Biological Chemistry · doi:10.1186/s13765-023-00842-x · Cited by 5 · see citing works

The impact of vaccination frequency on COVID-19 public health outcomes: A model-based analysisPreprint

Stoddard, M., Lin, Y., Sarkar, S., Egeren, D. V., Mangalaganesh, S., Nolan, R. P., Rogers, M. S., Hather, G., White, L. F., & Chakravarty, A. (2023) · medRxiv · doi:10.1101/2023.01.26.23285076 · Cited by 5 · see citing works

The Impact of Vaccination Frequency on COVID-19 Public Health Outcomes: A Model-Based Analysis

Yuan, L., Stoddard, M., Sarkar, S., Egeren, D. V., Mangalaganesh, S., Nolan, R. P., Rogers, M. S., Hather, G., White, L. F., & Chakravarty, A. (2025) · Vaccines · doi:10.3390/vaccines13040368 · Cited by 8 · see citing works

Immunobiology and immunotherapy of COVID-19

Lundstrom, K. H. (2025) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.12.002 · Cited by 3 · see citing works

SARS-COV-2 and Other mRNA Vaccines

Jackson, N. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_6

Перемога мРНК-вакцин над пандемією коронавірусу SARS-CoV-2, який викликає захворювання COVID-19, або як синтетична мРНК прослизнула повз вроджений імунний захист клітини

Комісаренко, С. В., & Романюк, С. И. (2023) · Visnik Nacional noi academii nauk Ukrai ni · doi:10.15407/visn2023.12.003

Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homogeneous and heterogenous neutralising antibody responses

Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2021) · doi:10.1101/2021.05.13.443734 · Cited by 18 · see citing works

Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses

Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2022) · Vaccines · doi:10.3390/vaccines10081251 · Cited by 22 · see citing works

Assessment of neutralizing antibody response as a correlate of protection against symptomatic SARS-CoV-2 infections after administration of two doses of the CoronaVac inactivated COVID-19 vaccine: A phase III randomized controlled trial

Chen, X., Meng, X., Wu, Q., Lim, W. W., Xin, Q., Cowling, B. J., Meng, W., Yu, H., & Covas, D. T. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106315 · Cited by 3 · see citing works

Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines

Karbiener, M., Farcet, M. R., Zollner, A., Masuda, T., Mori, M., Moschen, A. R., & Kreil, T. R. (2022) · npj Vaccines · doi:10.1038/s41541-022-00455-3 · Cited by 20 · see citing works

Vitamin D deficiency and inactivated SARS-CoV-2 vaccines

Wu, C., & Lu, K. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.09.005 · Cited by 1 · see citing works